$AMGN Rallies +4.84% on Oncology Catalyst, Bullish Crossover Signals Momentum Shift

$Amgen(AMGN)$

$Amgen, Inc. (AMGN) Surges +4.84%: Key Drug Approval Fuels Breakout, Eyes $359 Target 🚀

Latest Close Data 📈

• Closed at $354.06 on 2026-06-12, up +4.84% (+$16.33). The stock is now ~9.5% below its 52-week high of $391.29.

Core Market Drivers 💊

1. The primary catalyst is the EU Commission's recent approval of Imdylltra® for extensive-stage small cell lung cancer, opening a significant new revenue stream and solidifying Amgen's oncology portfolio.

2. Positive market sentiment is driving the breakout.

Technical Analysis 🔍

• Volume: Today's volume of 4.73M shares shows strong participation, with a Volume Ratio of 1.55 indicating above-average activity, confirming bullish conviction.

• MACD: The latest DIF (2.13) has crossed above the DEA (0.16), generating a bullish MACD crossover signal (value: 3.95). Momentum is shifting positive.

• RSI: The 6-day RSI at 68.71 is approaching overbought territory but not yet extreme, indicating strong short-term buying pressure.

Key Price Levels 🎯

• Immediate Pivot: $354.06 (Today's close). Holding above is key for continuation.

• Primary Support: ~$337.94 (Recent swing low). A break below could signal a pullback.

• Strong Resistance: ~$370.90 (Near-term ceiling). A decisive break above targets the 52-week high.

Valuation Perspective ⚖️

• Forward P/E (Latest): 15.82x, which is slightly above its historical average of ~14.86x. The P/S ratio of 5.12x reflects its premium, growth-biotech status.

Analyst Targets 🎯

• 30 analysts cover AMGN with an average price target of $359.29.

• Sentiment is Bullish: 4 Strong Buy, 13 Buy, 18 Hold, 2 Underperform, 1 Sell.

Weekly Outlook 📊

Expect consolidation near $354 with a bullish bias. A sustained move above $358 (today's high) could propel the stock towards the $359-$370 resistance zone. Failure to hold $350 may lead to a test of the $338 support.

Risk Disclaimer ⚠️ This analysis is for informational purposes only and not investment advice. Biotech stocks are volatile and subject to clinical trial results, regulatory changes, and market risks. Always conduct your own research and consult a financial advisor before trading.

😍 Been eyeing Tiger merch but short on Tiger Coins? Now's your chance.

🎁 We’ve selected 4 high-demand items across practial, lifestyle, and learning, now with a lower redemption threshold!

Hot Merch Returns · Up to 43% Off